BOOK NOW AND SAVE
UP TO €700

4th Annual Summit

ICI Europe

27-29 November, 2018
Berlin, Germany

www.immunecheckpoint-europe.com



Evidencing How Checkpoint Combinations can Enhance Every Stage of the Cancer Immunity Cycle

Expert Speakers Including:

Zhen Su
Senior Vice President & Chief Medical Officer, NA
Merck KGaA

Craig Blanchette
Senior Scientist
Genentech

Kris Sachsenmeier
Associate Director, Translational Science, IMED Oncology
AstraZeneca

Marlon Hinner
Group Leader, In Vitro Display
Roche

Frederic Triebel
CSO & CMO
Immutep

Tanja de Gruijl
Professor, Translational Tumor Immunology & Head of Immunotherapy Lab
VU University Medical Center

"Great conference, with a clear scientific focus, lots of networking opportunities and good interaction among participants"

Krzysztof Masternak, Head of Biology, NovImmune

Programme Partners

Personalis®

Tel: +44 203 141 8700 **Email:** info@hansonwade.com

Immune Checkpoint Inhibitors

hansonwade

Granular Insights to Enhance the Success of Your IO Pipeline

Returning for the 4th time, ICI Europe is the definitive forum focused exclusively on delivering maximum clinical benefit through immune checkpoint modulation.

Rather than covering a random selection of immuno-oncology combinations, ICI Europe focuses on how checkpoint combinations can impact every stage of the cancer immunity cycle, enhancing the long-term success of immuno-oncology drug development.

Cutting through the noise and hype around the immuno-oncology field, this industry focused conference will use the cancer immunity cycle as a framework from which to investigate the most promising checkpoint combination approaches.

Detailing combinations based exclusively on synergistic mechanisms rather than a 'hit-and-hope' combination approaches; **however you're approaching the immuno-oncology space, learn how you can engage a checkpoint backbone to enhance combination success**

> This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!
>
> **AstraZeneca**

> Great meeting, very informative, great to see what other companies are working on in the field of cancer immunotherapy
>
> **Genentech**

> Good mix of academic and pharma speakers. Overall the conference was a great success
>
> **GSK**

An Unparalleled Depth of Insights

1. Understand Why Some Immuno-Oncology Therapeutics Fail

Delve beyond the headlines to investigate the key factors underlying immuno-oncology failures and how to use this information to inform future development efforts

2. Interrogate the Role of the Innate Immune System

Engage the innate and adaptive immune responses to form a holistic anti-tumour immune response by learning how to leverage the role of NK cells, macrophages and dendritic cells

3. Investigate Translationally Relevant Preclinical Models

Bridge the gap between preclinical and clinical immuno-oncology development by understanding how innovative modelling approaches can represent the human immune system more accurately than ever before

4. Personalise Immunotherapies by Developing Complementary Biomarker Assays

Learn from in-depth analyses of patient-specific factors that have driven improved patient selection

5. Learn from Clinical Data Supporting the Scientific Rationale Behind Targeting Novel Checkpoint Pathways

Discover the true value of pathways such as TIGIT, CD73, LAG-3 and CD47, and understand how to exploit these most effectively through monotherapy and combination studies

Your Expert Speakers

Craig Blanchette
Senior Scientist
Genentech

Mathieu Blery
Senior Director, Translational Immunology
Innate Pharma

Jannie Borst
Divisional Head of Tumour Biology & Immunology
Netherlands Cancer Institute

Tanja de Gruijl
Professor, Translational Tumor Immunology & Head of Immunotherapy Lab
VU University Medical Center

Wolf-Dietrich Doecke
Director, Biomarker Strategist
Bayer

Walter Ferlin
Head of Exploratory Science & Translational Medicine
NovImmune

Tina Furebring
Vice President, Research & Development
Alligator Bioscience

Laura Helming
Director, Scientific Site Head, Immuno-Oncology
Merck KGaA

Marlon Hinner
Group Leader, In Vitro Display
Roche

Christian Hosius
Regional Director, Medical Affairs, Oncology
Merck Sharpe & Dohme

Zoë Johnson
CSO
iOnctura

Reece Marillier
Research Scientists, In Vivo Pharmacology
iTeos Therapeutics

Nicolo Rigamonti
Biology Lead & Project Leader, Cancer Immunology
Molecular Partners

Kris Sachsenmeier
Associate Director, Translational Science, IMED Oncology
AstraZeneca

Tim Sullivan
Vice President, Business Development
Arcus Biosciences

Zhen Su
Senior Vice President & Chief Medical Officer, NA
Merck KGaA

Frederic Triebel
CSO & CMO
Immutep

Markus Zettl
Director, Immuno-Oncology
Pieris Pharmaceuticals

Speaker to be confirmed
Personalis

> "It was a great conference, great selection of topics and speakers"
>
> **Berg Pharma**

WORKSHOPS

Pre-Conference Workshop Day | Tuesday, 27 November

Workshop A

Investigating Synergistic Checkpoint Modulator Targeting – How Can We Select Rational Combinations?

9.00 – 12.00

Multispecific formats clearly demonstrate opportunities to achieve a greater efficacy than combinations of individual mAbs in targeting checkpoint modulating targets.

Addressing the key challenge of the identification and selection of synergistic targets, this workshop will:

- Investigate our mechanistic understanding of checkpoint inhibition to guide future targeting strategies
- Share how bispecifics can add most value in comparison to standard of care combinations

Workshop Leader

Tina Furebring, Vice President, Research & Development, **Alligator Bioscience**

Dr. Furebring joined Alligator Bioscience in 2001, as a SVP R&D she is responsible for the pipeline program consisting of mono and bispecific antibodies for tumor directed immunotherapy of cancer . Dr. Furebring has more than 20 years of experience with protein and antibody optimization as well as generation of antibodies using phage display. Dr. Furebring completed her PhD in Immunotechnology from Lund University, Sweden.

Workshop B

Investigating the Factors Influencing T Cell Priming and How this Process Can be Enhanced Therapeutically

13.00 – 16.00

CD8 T cells differentiate after their activation into effector and memory cytotoxic T cells (CTLs). How well these CTLs can perform their effector and memory functions is largely dictated by the conditions during their initial activation in lymphoid organs.

Sharing an in-depth insight into the effects of this initial T cell priming, this workshop will:

- Provide you with insights into the benefits of T-cell priming within the tumour in tertiary lymphoid organs
- Present data to give you a better understanding of the educational niches where functional help can be given to cytotoxic T-cells

Workshop Leader

Jannie Borst, Divisional Head of Tumour Biology & Immunology, **Netherlands Cancer Institute**

Jannie Borst obtained an MSc degree in biology with chemistry and a PhD degree in molecular immunology from Leiden University. She did her PhD work at Harvard Medical School in Boston with biochemist dr Cox Terhorst and trained in immunology with drs Jan de Vries and Hergen Spits from 1980 to 1985. She has authored 170 peer-reviewed papers (H-index 71, >15.000 citations). Major contributions have been to the understanding of antigen recognition-, costimulatory receptor- and death receptor functions on lymphocytes. She currently studies the molecular basis of T-cell and dendritic cell function, a.o. by transcriptomics and proteomics. This work aims to improve cancer immunotherapy. To this end, collaborations with biotech, pharma and clinicians are in place.

Conference Day One | Wednesday, 28th November

7.50 **Registration and Networking**

Zhen Su
Senior Vice President & Chief Medical Officer, NA
Merck KGaA

8.20 **Chairs Opening Remarks**

Understanding How Immuno-Oncology is Changing the Oncology Landscape

Zhen Su
Senior Vice President & Chief Medical Officer, NA
Merck KGaA

8.30 **Keynote – Evaluating How the Immuno-Oncology Therapies Have Changed the Standard of Care in Oncology & What This Means for the Field & Patients**

- Learning how immuno-oncology has shifted the paradigm of patient treatment and management
- Understanding the rapid evolution of the standard of care in a variety of indications
- Investigating how patient populations have changed given the ubiquity of checkpoint modulators and the effects this will have on clinical development and real-world practice

Kris Sachsenmeier
Associate Director, Translational Science, IMED Oncology
AstraZeneca

9.00 **Keynote – Adenosine-mediated Immunosuppression: Escape From First Generation Checkpoint Inhibitors**

- Update on adenosine-mediated immunosuppression
- Adenosine signaling vs. generation: When to target which?
- Targeting innate immunity when adaptive immunity fails
- Review of reasons for clinical anti-PD(L)1 failure

Speaker to be confirmed
Personalis

9.30 **Presentation Details to Be Confirmed**

10.00 **Speed Networking & Morning Refreshments**

Developing Reliable, Translatable & Meaningful Preclinical Models

Reece Marillier
Research Scientists, In Vivo Pharmacology
iTeos Therapeutics

11.15 **Preclinical Mouse Models to Support the Rapid Development of Innovative Immuno-Oncology Therapeutics**

- Understanding the data that can be extracted from preclinical models – what information can be gained and how can we use these insights
- Sharing the key aspects of the preclinical development of an A2A antagonist
- Investigating preclinical biomarker identification approaches to use in the clinic

11.45 **Roundtable session: What Makes a Good Model? Contrasting Available Preclinical Modelling Approaches to Enhance Translation into the Clinic**

Drive your own learning and crowd-source ideas. Discover multiple perspectives on the key features that make an effective animal model, by joining roundtable discussions that have been specifically designed to enable you to leave with insights that you can immediately implement into your own drug development programs.

1 Humanised Mouse Models

2 3D Models

3 PDx Models

4 In Silico Modelling Approaches

12.30 Lunch & Networking

Cancer Immunity Cycle Stages 1-3
Release of Antigen, Priming & Activation

The first steps of the cancer immunity cycle involve the creation of neoantigens by oncogenesis, then the capture and presentation of these antigens to T cells, leading to the priming and activation of effector T cell responses against the cancer-specific antigens. The talks in this section therefore focus on the factors influencing T cell priming and activation, putting the 'foot on the gas' to improve the likelihood of successfully 'taking the foot off the brake' later on.

Tanja de Gruijl
Professor, Translational Tumor Immunology & Head of Immunotherapy Lab
VU University Medical Center

13.30 Therapeutic Modulation of the Microenvironment of Tumour-Draining Lymph Nodes Through Local Administration of TLR Agonists or Immune Checkpoint Inhibitors

- Immune suppression in tumour-draining lymph nodes (TDLN) will seriously hamper local and systemic tumour control
- (Pre-)clinical evidence points to the possibility of reducing (distant) tumour recurrence rates through local low-dose immune modulation of TDLN in early-stage cancer
- Multi-parameter profiling and ex-vivo cultures of TDLN samples provide a basis for the selection of clinically applicable immune checkpoint inhibitors and/or TLR agonists for different tumour indications

Frederic Triebel
CSO & CMO
Immutep

14.00 Two ACTive Immunotherapies (TACTI): Results of a Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3Ig Or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrolizumab

- LAG-3/MHC class II interactions and their modulation in both cancer and auto-immune diseases
- Combination therapy with eftilagimod alpha (LAG-3Ig) and chemotherapy or anti-PD-1 mAb
- Presentation of an ongoing Phase II Trial in NSCLC and HNSCC (TACTI-002)

14.30 Afternoon Break & Refreshments

Markus Zettl
Director, Immuno-Oncology
Pieris Pharmaceuticals

15.00 Presentation Details to be Confirmed

Zoë Johnson
CSO
iOnctura

15.30 PI3Kδ: A New Era in Immuno-Oncology

- The scientific rationale for PI3Kδ as a novel immune checkpoint
- Preclinical development of a unique PI3Kδ inhibitor for immune-oncology
- Clinical development plans for IOA-244 as a monotherapy and in combination with traditional checkpoint blockade

Zhen Su
Senior Vice President & Chief Medical Officer, NA
Merck KGaA

16.00 Chair's Closing Remarks

16.15 Close of Conference Day 1

Conference Day Two | Thursday, 29th November

8.30 Registration and Networking

Jannie Borst
Divisional Head of Tumour Biology & Immunology
Netherlands Cancer Institute

8.50 Chairs Opening Remarks

Personalising Immunotherapy Through Innovative Biomarker Approaches

Craig Blanchette
Senior Scientist
Genentech

9.00 Developing a Personalized Immune Monitoring Program: Applications to Personalised Cancer Vaccine (PCV) Therapeutics

- The success of cancer immunotherapy drugs is going to be dependent on the development of biomarkers to better understand the effect of treatment on neoantigen T-cell responses
- Effective implementation of personalised cancer immunotherapies will require the development of complementary personalised biomarker assays
- Developing a personalized biomarker program involving patient-specific MHCI tetramers requires robust and automated quality control assays and validated FACs panels

Christian Hosius
Regional Director, Medical Affairs, Oncology
Merck Sharpe & Dohme

9.30 Enhancing the Clinical Development of Checkpoint Modulators as Monotherapies and in Combination

- Examining the key factors that have led to success in combination trials involving checkpoint modulators
- Optimising patient selection to enhance immuno-oncology clinical trials
- Examining biomarker strategies to better personalise cancer immunotherapy

Wolf-Dietrich Doecke
Director, Biomarker Strategist
Bayer

Craig Blanchette
Senior Scientist
Genentech

Zhen Su
Senior Vice President & Chief Medical Officer, NA
Merck KGaA

Christian Hosius
Regional Director, Medical Affairs, Oncology
Merck Sharpe & Dohme

10.00 Panel Discussion: Investigating Biomarkers to Predict Responses to Immunotherapy: Which Factors in the Biological Profile of the Patient Should We Assess?

- What is the best strategy to assess imaging techniques, mutational analysis, signalling pathway assessment, neo-antigen generation and a range of other factors
- Tailoring analysis based on stage of the tumour and characteristics of the patient
- Is this level of personalisation realistic and attainable?
- Integrating omic approaches to give a comprehensive insight into potentially predictive signatures – aligning genomics, epigenetics and transcriptomics
- Standardising approaches to biopsies, storage of samples and biomarker analysis
- Investigating a wide array of parameters simultaneously to gain a detailed impression of the tumour microenvironment before and during therapy
- Revealing the latest sequencing approaches to give an unprecedented amount of real-time detail

10.45 Morning Refreshments & Networking

Cancer Immunity Cycle Stages 4-7
Migration, Infiltration & Cancer Cell Killing

In the latter stages of the cycle, activated effector T cells are trafficked to and infiltrate the tumor bed where they recognise and kill their target cancer cells. The talks in this section tie into this part of the cycle, focussing on assisting T cells in cancer killing and exploring the cell types in the tumour microenvironment that can enhance the efficacy of cancer cell killing.

Jannie Borst
Divisional Head of Tumour Biology & Immunology
Netherlands Cancer Institute

11.15 Enticing Cytotoxic T Cells to Attack Cancer: The Importance of CD4 T Cell Help

- CD4- and CD8 T cells are activated by dendritic cells that present antigens, provide costimulatory signals and cytokines that together activates T cells to proliferate and differentiate
- In a newly acknowledged second encounter with lymph node resident dendritic cells, CD4 T cell help for the CTL response is delivered, via specific costimulatory- and cytokine receptors
- The functional capacities that a CTL needs to effectively reach, penetrate into and kill a tumour cell mass are instructed at the gene expression and epigenetic level as a result of CD4 T cell help
- CD4 T cell help can be exploited to improve cancer immunotherapy efficacy, by inclusion of helper epitopes in vaccines, by using CD4 T cells and dendritic cells to educate tumour-specific CD8 T cells in vitro, by targeting the dendritic cells that transmit CD4 T cell help in vivo and by engaging costimulatory and cytokine receptors that are key in help transmission

Tim Sullivan
Vice President, Business Development
Arcus Biosciences

11.45 Discovery & Development of AB154, a Novel Antibody Targeting TIGIT

- Outlining the scientific rationale behind targeting the TIGIT:CD155 interaction
- Sharing key findings from the progression of AB154, anti-TIGIT antibody
- Investigating potential combinations involving TIGIT targeting therapeutics

12.15 Lunch & Networking

Unleashing the Potential of Innate & Adaptive Anti-Tumour Immune Responses

Laura Helming
Director, Scientific Site Head, Immuno-Oncology
Merck KGaA

13.15 Enhancing Anti-Tumour Activity by Targeting the Tumour Microenvironment

- Building upon checkpoint inhibition but going beyond: addressing immunosuppressive mechanisms and myeloid cells/phagocytes in the tumour microenvironment
- M7824, a novel bifunctional fusion protein targeting PD-L1 and TGF-β
- Immunsuppression by MDSCs: screening to identify therapeutic targets

Mathieu Blery
Senior Director, Translational Immunology
Innate Pharma

13.45 Next Generation Immunotherapies: Targeting Innate Lymphocytes and Tumour Microenvironment

- What can we learn from past experiences of targeting innate immune cell types? Analysing the data to inform future studies
- Beyond T cells – targeting NK cells, myeloid cells and the adenosine pathway
- Insights into biomarker approaches to enhance the preclinical and clinical development of immuno-oncology therapeutics

Walter Ferlin
Head of Exploratory Science & Translational Medicine
NovImmune

14.15 Gaining Insights Into the Development of CD47-Targeting Therapeutics

- Understanding the rationale behind targeting the CD47 "Do Not Eat" signal
- Presenting clinical insights from the progression of CD47-targeting therapeutics
- Investigating potential combination strategies

14.45 Afternoon Refreshments & Networking

Investigating Innovative Therapeutic Constructs to Address Immuno-Oncology Targets More Effectively

Nicolo Rigamonti
Biology Lead & Project Leader, Cancer Immunology
Molecular Partners

15.15 Fibroblast Activation Protein (FAP)-Selective Delivery of CD40 Agonistic DARPin® Protein for Tumour-Localized Immune Activation

- DARPin® Proteins: Beyond the target space of antibodies
- Development of a bispecific DARPin® protein to activate CD40 locally at the tumour site to reduce systemic toxicity and improve efficacy of cancer immunotherapy
- Presenting data demonstrating a FAP-dependent activation of CD40 and subsequent tbiological response on different immune cell subsets through an innovative CD40 agonist DARPin® protein

Marlon Hinner
Group Leader, In Vitro Display
Roche

Walter Ferlin
Head of Exploratory Science & Translational Medicine
NovImmune

Nicolo Rigamonti
Biology Lead & Project Leader, Cancer Immunology
Molecular Partners

15.45 Panel Discussion: Contrasting Therapeutic Modalities in Immuno-Oncology

- Understanding the value of bispecific therapeutics and assessing the advantages and disadvantages in comparison with monoclonal antibody combinations
- Assessing the characteristics of immuno-oncology targets that influence the choice of therapeutic construct
- Addressing logistical challenges encountered in developing novel combinations
- Understand the strengths and limitations of various cancer immunotherapy treatment modalitites and understand how the therapeutic landscape has changed throughout the explosion of immuno-oncology development
- Explore the future of immuno-oncology therapeutic design

Jannie Borst
Divisional Head of Tumour Biology & Immunology
Netherlands Cancer Institute

16.15 Chair's Closing Remarks

16.30 Close of Conference

PARTNER WITH US

Are you front of mind when biopharma companies look externally for assistance in the development of immuno-oncology therapeutics?

ICI Europe will bring together senior decision makers from drug developer organizations who are committed to enhancing the efficacy of immuno-oncology therapeutics.

These attendees are actively seeking expertise and technologies to help make the next generation of IO drugs a reality. Therefore, this meeting will offer you a valuable platform to showcase your solutions, generate new business leads and source opportunities for partnerships. Engage directly with key pharmaceutical and biotech companies pioneering this field, to stay ahead of the curve and maximise the wealth of opportunities on offer.

To find out more, email sponsor@hansonwade.com

ATTENDANCE BY SECTOR



* Based on attendee breakdown from ICI Europe 2017

CONFIRMED PARTNER

Personalis®

Programme Partner

Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies.

www.personalis.com

"A very informative meeting with all the major players in the field present"

Genscript, Previous ICI Partner

"A valuable business and educational opportunity in a rapidly growing field"

Immudex, Previous ICI Partner

BECOME A PARTNER

Nathan Wilgoss
Partnerships Manager
T. +44 (0)20 3141 8700
E. sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.immunecheckpoint-europe.com

Tel: +44 203 141 8700

Email: register@hansonwade.com

1. Investigate the rationale behind immuno-oncology strategies to engage the holistic anti-tumour immune response
2. Improve your clinical success rate by learning how to stratify and select patients more effectively
3. Bridge the gap to the clinic by investigating novel preclinical modelling approaches

Team Discounts*

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5 or more delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

SECURE YOUR PLACE

Package Details	Save €700 - Register and Pay by Friday, 7 September	Standard Rate
PLATINUM - Conference + 2 Workshops **(Save €300)**	€2,797	€3,497
GOLD - Conference + 1 Workshop **(Save €200)**	€2,298	€2,998
SILVER Conference Only	€1,899	€2,599
BRONZE Workshops (Each)	€599	

*VAT will be charged at 19%

Academic and Not for Profit Organizations are entitled to a 40% discount off the Industry Pricing using the code 'ACA'
(Please note: No further discounts are applicable)



VENUE

Sofitel Berlin Kurfuerstendamm
Augsburger Str. 41, 10789 Berlin, Germany

For further information or assistance, please visit www.sofitel-berlin-kurfuerstendamm.com

Code: 9710